References
- Harris N L, Jaffe E S, Stein H, Banks P M, Chan J K, Cleary M L, et al. Lymphoma classification proposal: clarification. Blood 1995; 85: 857–860
- McLaughlin P, Grillo-Lopez A J, Link B K, Levy R, Czuczman M S, Williams M E, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833
- Lok A SF, Lai C L, Wu P C. Hepatitis B virus infection in Chinese families in Hong Kong. Am J Epidemiol 1987; 126: 492–499
- Dursun M, Ertem M, Yılmaz S, Gunay S, Tuncer O, Zeynep S. Prevalence of hepatitis B infection in the southeastern region of Turkey: comparison of risk factors for HBV infection in rural and urban areas. Jpn J Infect Dis 2005; 58: 15–19
- Steinberg J L, Yeo W, Zhong S, Chan J YH, Tam J S, Chan P KS, et al. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role. J Med Virol 2000; 60: 249–255
- Yeo W, Chan P KS, Zhong S, Ho W M, Steinberg J L, Tam J S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy. a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299–307
- Hanson R G, Peters M G, Hoofnagle J H. Effects of immunosuppressive therapy with prednisolone on B and T lymphocyte function in patients with chronic type B hepatitis. Hepatology 1986; 6: 173–179
- Wands J R. Subacute and chronic active hepatitis after with-drawal of chemotherapy (letter). Lancet 1975; 2: 979
- Liag R, Lau G KK, Kwong Y L. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis carriers: a review of the problem. J Clin Oncol 1999; 17: 394–398
- Borg F T, Smorenburg S, De Man R A, Rietbroek R C, Chamuleau R, Jones E A. Recovery from life-threatening corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy. Dig Dis Sci 1998; 43: 2267–2270
- Clark F L, Drummond M W, Chambers S, Chapman B A, Patton W N. Successful treatment of lamivudine for fulminant hepatitis B infection following intensive therapy for high grade non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 385–387
- Yeo W, Chan P KS, Ho W M, Zee B, Lam K C, Lei K IK. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004; 22: 927–934
- Tsutsumi Y, Kawamura T, Saitoh S, Yamada M, Obara S, Miura T, et al. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis virus reactivation in rituximab therapy. Leuk Lymphoma 2004; 45: 627–629
- Law J K, Ho J K, Hoskins P J, Erb S R, Steinbrecher U P, Yoshida E M. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005; 46: 1085–1089
- Leonard J P. Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates. Hematology 2005; 335–339